GLP-1 was discovered by Svetlana Mojsov and Joel Habener in the early 1980s [48,49,50]
Providers may prescribe GLP-1 or GIP-based medications such as semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro) when clinically appropriate
Reduces Inflammation: Chronic inflammation is at the root of many health problems, including skin conditions, joint pain, and cardiovascular diseases
PubMed Peptide bioregulators: the new class of geroprotectors
Nausea, fatigue, and GI discomfort are common during initiation
(Novo Nordisk also sells Ozempic, a slightly different form of semaglutide.) Prior research had already confirmed semaglutide/Wegovy can help overweight and obese patients lose weight